STOCK TITAN

Milestone Scient - MLSS STOCK NEWS

Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.

Comprehensive Overview

Milestone Scient (MLSS) is a pioneering company in the field of medical technology, specializing in computer-controlled local anesthetic delivery systems. With a commitment to enhancing patient comfort and clinical precision, the company has developed innovative systems that transform traditional injection techniques into a streamlined, virtually painless process. Operating across the dental and medical sectors, MLSS integrates advanced technology with ergonomic design to deliver solutions that cater to a broad spectrum of procedures.

Technology and Innovation

The core of MLSS's success lies in its proprietary technology, which focuses on computer-controlled delivery of local anesthetic agents. By automating the injection process, these systems ensure a controlled, gradual administration of anesthetic, markedly reducing discomfort and anxiety for patients. The technology uses precise algorithms and sensor-driven feedback to tailor the injection speed and pressure, providing a remarkable improvement over traditional manual methods.

Product Applications and Clinical Utility

MLSS's product portfolio is divided into two primary segments: Dental and Medical. In dentistry, the systems are marketed under trademarks that emphasize the technology's capacity for painless procedures, supporting a wide array of dental treatments ranging from routine cleanings and fillings to more complex procedures such as implants, root canals, and crowns. In the medical field, the applications extend to procedures in plastic surgery, hair restoration surgery, podiatry, colorectal surgery, dermatology, and orthopedics. These systems are engineered to ensure precision and reliability, making them suitable for diverse clinical applications.

Market Position and Global Reach

As an established player in the medical device segment, MLSS has solidified its position through a combination of technological innovation and strategic market penetration. The company’s systems are marketed and sold not only across the United States but also in over 25 countries, underscoring its global presence. MLSS's commitment to research and development and its focus on combining state-of-the-art technology with user-centric design have allowed it to navigate the competitive medtech landscape effectively. The company's ability to address clinical challenges through innovation has resonated with practitioners, helping to foster trust and reliability in its products.

Operational Excellence and Strategic Insights

MLSS operates with a dual-segment strategy focusing on both dental and medical markets, ensuring that its technological advancements impact a wide range of clinical practices. The systems, designed with precision and reliability, offer enhanced control during administration, making them indispensable tools in modern clinical settings. The company's strategic initiatives, including efforts to improve reimbursement strategies and expand its clinical adoption, are reflective of its robust operational framework. Moreover, MLSS maintains an emphasis on continuous innovation and partnerships which further bolster its position within the competitive landscape.

Why MLSS Stands Out

Two defining characteristics set Milestone Scient apart: its commitment to eliminating patient discomfort and its advanced, computer-controlled delivery technology. By converting complex manual procedures into automated precision processes, MLSS significantly reduces the challenges associated with traditional anesthetic administration. The integration of sophisticated control systems and real-time monitoring has not only refined the delivery process but also contributed to more consistent clinical outcomes.

Industry Keywords and Insights

Key industry terms such as computer-controlled injection, local anesthetic delivery, and painless injection technology are integral to understanding the value proposition of MLSS. These terms encapsulate the company’s strategic focus on blending technology with clinical expertise to provide superior, patient-centered solutions.

Conclusion

Milestone Scient represents a significant evolution in the realm of local anesthetic administration. By combining advanced technology with an acute understanding of clinical needs, the company has developed systems that offer both reliability and exceptional patient comfort. With robust global distribution and a comprehensive portfolio that addresses diverse clinical procedures, MLSS continues to set benchmarks in precision, efficiency, and patient care. The detailed approach to technological innovation and product efficacy makes MLSS a critical player in its industry, consistently enhancing the landscape of medical and dental care.

Rhea-AI Summary
Milestone Scientific Inc. (MLSS) announces the commencement of sales of CompuFlo® Epidural disposables into PRC Alliance Pain Relief Center in Florida. Dr. Bakshi reports 100% success in Epidural Steroid Injection procedures, praising the system for enhancing speed and safety. Milestone Scientific aims to advance sales of their technology in pain clinics nationwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Milestone Scientific Inc. reports a successful year in 2023 with revenue up by 11.6% and gross profit increasing by 39%. The company attributes this growth to the success of its new online sales portal for the STA Single Tooth Anesthesia System® in the U.S. The CEO, Arjan Haverhals, highlights the termination of the prior exclusive distributor in 2022 and the successful transition to a direct sales model. The company is also focusing on international expansion in 2024. Milestone Scientific is advancing the rollout of the CompuFlo® Epidural System, with progress in penetrating key hospitals and pain management clinics. The company is working on accelerating reimbursement claims submission and has seen a significant increase in claims activity. Financially, the company ended 2023 with approximately $6.0 million in cash, cash equivalents, and marketable securities, showing confidence in executing its growth strategy without additional funds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.84%
Tags
none
-
Rhea-AI Summary
Milestone Scientific Inc. (MLSS) will host a conference call to discuss its financial results for 2023 and corporate progress on April 1, 2024. The call will be available via telephone and webcast, with an audio replay option until April 15, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
Rhea-AI Summary
Milestone Scientific Inc. (NYSE:MLSS) announces the commencement of sales of CompuFlo® Epidural disposables to Omaha Pain Physicians, following a successful evaluation by Dr. Matthew Stottle, reporting 100% success rate in 10 cases. The technology offers safety enhancements for Epidural Steroid Injection procedures, reinforcing the ongoing success and safety of the CompuFlo system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
none
-
Rhea-AI Summary
Milestone Scientific Inc. (MLSS) announces the commencement of direct sales of its STA Single Tooth Anesthesia System® with Meridian Endo & Perio, a dental practice in Wisconsin. The system is praised for its ease of use and patient comfort, leading to expanded adoption within the practice. The CEO highlights the benefits of the new direct sales model and anticipates steady revenue growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
none
-
Rhea-AI Summary
Milestone Scientific Inc. (MLSS) announces the commencement of sales of its STA Single Tooth Anesthesia System® with Maine Dental Group. The agreement reflects the success of their new sales strategy targeting Dental Service Organizations (DSOs) and large group practices. The partnership aims to enhance patient experience, improve practice efficiency, and drive greater awareness of Milestone's technology in the dental industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Milestone Scientific Inc. (MLSS) reports initial reimbursements of CompuFlo® by commercial payors and Medicare. The CEO, Arjan Haverhals, updates shareholders on the successful commercialization of the CompuFlo technology and the positive traction it has gained. The company has received FDA clearance for expanded use of the technology and has launched a reimbursement plan to support pain management providers. The advisory sites implementing CompuFlo technology have reported a 100% success rate for patient procedures, with zero dural punctures. The University of Texas Medical Branch (UTMB) Health Clear Lake Campus Hospital has expanded the use of CompuFlo beyond the labor and delivery department, demonstrating the positive clinical feedback received. The company is focused on increasing the number of CompuFlo providers in the US and accelerating patient access to the technology through ongoing education and engagement with payors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
-
Rhea-AI Summary
Milestone Scientific Inc. (NYSE:MLSS) closed a public offering of 4,765,000 shares of common stock at $0.63 per share, generating approximately $3.0 million in gross proceeds. The underwriter has a 45-day option to purchase up to an additional 714,750 shares. The Offering was disclosed in a final prospectus supplement on December 12, 2023, following the registration statement's effectiveness on October 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
-
Rhea-AI Summary
Milestone Scientific Inc. (NYSE:MLSS) has announced the pricing of an underwritten public offering of 4,765,000 shares of its common stock at a price of $0.63 per share, expected to generate approximately $3.0 million in gross proceeds. The Offering is expected to close on December 13, 2023, with Maxim Group LLC acting as the sole book-runner. The Company has also granted the underwriter a 45-day option to purchase up to an additional 714,750 shares of common stock on the same terms and conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.68%
Tags
Rhea-AI Summary
Milestone Scientific Inc. (NYSE:MLSS) has commenced an underwritten public offering of shares of its common stock, with an option to purchase additional shares. Maxim Group LLC is acting as the sole book-runner for the Offering. The Offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-275088) previously filed with the U.S. Securities and Exchange Commission ('SEC').
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.68%
Tags

FAQ

What is the current stock price of Milestone Scient (MLSS)?

The current stock price of Milestone Scient (MLSS) is $0.91 as of April 22, 2025.

What is the market cap of Milestone Scient (MLSS)?

The market cap of Milestone Scient (MLSS) is approximately 75.0M.

What does Milestone Scient specialize in?

Milestone Scient specializes in developing and manufacturing computer-controlled local anesthetic delivery systems for both dental and medical applications. Their systems are designed to provide painless, precise, and controlled delivery of local anesthetic.

How are the company’s products utilized in clinical settings?

The products are used to automate and control the injection of local anesthetics, enhancing patient comfort and clinical precision. They support a range of procedures in dentistry and medicine, from routine treatments to more complex surgeries.

In which markets does Milestone Scient operate?

Milestone Scient operates in both the dental and medical markets, offering solutions that cater to various clinical procedures. Their products are distributed domestically within the United States and internationally in over 25 countries.

What are the technological advantages of the company's systems?

The systems use computer-controlled algorithms and sensor feedback to deliver anesthetic agents in a precise, controlled manner. This technology reduces patient discomfort and improves the accuracy of injections compared to traditional manual techniques.

How does Milestone Scient ensure the efficacy of its delivery systems?

The company invests in continuous research and development to refine its technology. Their systems are rigorously tested and are designed to adapt to various clinical needs while maintaining high levels of precision and reliability.

How does the company differentiate itself from competitors?

MLSS differentiates itself through its proprietary, computer-controlled technology that offers improved patient comfort and clinical efficiency. Its dual-segment approach in dental and medical markets further enhances its competitive edge.

What clinical procedures benefit from the company’s technology?

Both routine dental procedures like cleanings and fillings and complex medical procedures in fields such as plastic surgery, dermatology, and orthopedics benefit from the precision and reliability of MLSS's anesthetic delivery systems.

What drives Milestone Scient's global market presence?

The company’s global presence is driven by its innovative technology, robust operational strategies, and the growing demand for precise, painless anesthetic delivery systems in various clinical settings. Its commitment to quality and strategic partnerships further supports its international expansion.
Milestone Scient

NYSE:MLSS

MLSS Rankings

MLSS Stock Data

74.95M
60.65M
22.9%
5.7%
0.11%
Medical Instruments & Supplies
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
LIVINGSTON